Cargando…
Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma
Ipilimumab, a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody that potentiates antitumor T-cell responses, has demonstrated improved survival in previously treated and treatment-naïve patients with unresectable stage III/IV melanoma. Survival benefit has also been shown in dive...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665248/ https://www.ncbi.nlm.nih.gov/pubmed/23738073 http://dx.doi.org/10.1155/2013/423829 |
_version_ | 1782271238369968128 |
---|---|
author | Chmielowski, Bartosz |
author_facet | Chmielowski, Bartosz |
author_sort | Chmielowski, Bartosz |
collection | PubMed |
description | Ipilimumab, a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody that potentiates antitumor T-cell responses, has demonstrated improved survival in previously treated and treatment-naïve patients with unresectable stage III/IV melanoma. Survival benefit has also been shown in diverse patient populations, including those with brain metastases. In 2011, ipilimumab (3 mg/kg every 3 weeks for 4 doses) was approved by the Food and Drug Administration for unresectable or metastatic melanoma. Ipilimumab can induce novel response patterns for which immune-related response criteria have been proposed. irAEs are common but are usually low grade; higher grades can be severe and life-threatening. irAEs are usually manageable using established guidelines emphasizing vigilance and prompt intervention. This agent provides an additional therapeutic option in metastatic melanoma, and guidelines for management of adverse events facilitate clinical implementation of this new agent. |
format | Online Article Text |
id | pubmed-3665248 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-36652482013-06-04 Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma Chmielowski, Bartosz J Skin Cancer Review Article Ipilimumab, a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody that potentiates antitumor T-cell responses, has demonstrated improved survival in previously treated and treatment-naïve patients with unresectable stage III/IV melanoma. Survival benefit has also been shown in diverse patient populations, including those with brain metastases. In 2011, ipilimumab (3 mg/kg every 3 weeks for 4 doses) was approved by the Food and Drug Administration for unresectable or metastatic melanoma. Ipilimumab can induce novel response patterns for which immune-related response criteria have been proposed. irAEs are common but are usually low grade; higher grades can be severe and life-threatening. irAEs are usually manageable using established guidelines emphasizing vigilance and prompt intervention. This agent provides an additional therapeutic option in metastatic melanoma, and guidelines for management of adverse events facilitate clinical implementation of this new agent. Hindawi Publishing Corporation 2013 2013-04-21 /pmc/articles/PMC3665248/ /pubmed/23738073 http://dx.doi.org/10.1155/2013/423829 Text en Copyright © 2013 Bartosz Chmielowski. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Chmielowski, Bartosz Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma |
title | Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma |
title_full | Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma |
title_fullStr | Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma |
title_full_unstemmed | Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma |
title_short | Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma |
title_sort | ipilimumab: a first-in-class t-cell potentiator for metastatic melanoma |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665248/ https://www.ncbi.nlm.nih.gov/pubmed/23738073 http://dx.doi.org/10.1155/2013/423829 |
work_keys_str_mv | AT chmielowskibartosz ipilimumabafirstinclasstcellpotentiatorformetastaticmelanoma |